Open AccessValidation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma
Author(s) -
Benjamin M. Ellingson,
Lauren E. Abrey,
Sarah J. Nelson,
Timothy J. Kaufmann,
Josep Garcia,
Olivier Chinot,
Frank Saran,
Ryo Nishikawa,
Roger Henriksson,
W. P. Mason,
Wolfgang Wick,
Nicholas Butowski,
Keith L. Ligon,
Elizabeth R. Gerstner,
Howard Colman,
John de Groot,
Susan M. Chang,
Ingo K. Mellinghoff,
Robert J. Young,
Brian M. Alexander,
Rivka R. Colen,
Jennie Taylor,
Isabel ArrillagaRomany,
Arnav Mehta,
Raymond Y. Huang,
Whitney B. Pope,
David A. Reardon,
Tracy T. Batchelor,
Michael D. Prados,
Evanthia Galanis,
Patrick Y. Wen,
Timothy F. Cloughesy
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy053
Subject(s) - medicine , oncology , bevacizumab , clinical trial , hazard ratio , chemoradiotherapy , radiation therapy , chemotherapy , confidence interval
In the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial consortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom